Eikon Therapeutics, Inc. (EIKN) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
Open the full interactive Eikon Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Eikon Therapeutics Key Stats
| Share Price | $6.72 |
|---|---|
| 52-Week Range | $6.72 – $16.26 |
| Shares Outstanding | 54.1 million (basic, 2026 Q2) |
Eikon Therapeutics Quarterly Results
| 2026 Q1 | 2026 Q2 | |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income | -$83.0M | -$88.4M |
| Diluted EPS | -$2.46 | -$1.63 |
Figures from Eikon Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Eikon Therapeutics financials page for every line item.
Eikon Therapeutics Company Profile
| Ticker | EIKN |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Millbrae, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001861123 |
Eikon Therapeutics Competitors & Similar Companies
ENTXEntera Bio Ltd.ENGNenGene Holdings Inc.TNYATenaya Therapeutics, Inc.LENZLENZ Therapeutics, Inc.BDTXBlack Diamond Therapeutics, Inc.ELOXEloxx Pharmaceuticals, Inc.HUMAHumacyte, Inc.CGEMCullinan Therapeutics, Inc.
See all 136 Biological Products, (No Diagnostic Substances) companies →